Search Result

Results for "

Abl

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcr-Abl (135) AAK1 (1) Ack1 (1) Akt (3) Antibiotic (1) Apoptosis (32) Aurora Kinase (9) Autophagy (31) Bacterial (1) Bcl-2 Family (1) BCRP (1) c-Fms (1) c-Kit (16) c-Met/HGFR (1) c-Myc (1) CaMK (1) Casein Kinase (1) CDK (2) CRISPR/Cas9 (1) Cyclin G-associated Kinase (GAK) (1) Deubiquitinase (1) Discoidin Domain Receptor (3) Drug Metabolite (7) E3 Ligase Ligand-Linker Conjugates (1) EGFR (2) Ephrin Receptor (2) Ferroptosis (2) FGFR (6) FLT3 (10) Fluorescent Dye (1) HDAC (1) Histone Methyltransferase (1) IGF-1R (1) Isotope-Labeled Compounds (6) JAK (7) Ligands for E3 Ligase (7) Ligands for Target Protein for PROTAC (5) LIM Kinase (LIMK) (2) MAP4K (1) MAPKAPK2 (MK2) (1) Microtubule/Tubulin (2) p38 MAPK (1) Parasite (1) PDGFR (21) PI3K (1) PKD (1) PROTACs (9) Raf (4) RET (3) Salt-inducible Kinase (SIK) (2) SARS-CoV (6) Small Interfering RNA (siRNA) (4) SNIPERs (12) Src (31) STAT (5) Thymidylate Synthase (1) Tyrosinase (1) ULK (2) VEGFR (9) Wee1 (1)
By Research Areas:	Cancer (165) Cardiovascular Disease (1) Endocrinology (1) Infection (3) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (9)
Oligonucleotides:	Pre-designed siRNA Sets (4) siRNAs (4)

186

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Bcr-Abl

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-104010

Asciminib 5 Publications Verification Abl001	Bcr-Abl	Cancer
Asciminib (ABL001) is a potent and selective allosteric *BCR-ABL1* inhibitor, which inhibits Ba/F3 cells grown with an IC₅₀ of 0.25 nM .

HY-104010A

Asciminib hydrochloride 5 Publications Verification Abl001 hydrochloride	Bcr-Abl	Cancer
Asciminib (ABL001) hydrochloride is a potent and selective allosteric *BCR-ABL1* inhibitor, which inhibits Ba/F3 cells grown with an IC₅₀ of 0.25 nM .

HY-108317

ABL127	Others	Cancer
ABL127 is a selective and covalent inhibitor of protein methylesterase 1 (PME-1) with IC₅₀s of 6.4 nM and 4.2 nM in HEK293T and MDA-MB-231 cells, respectively.

HY-135635

ABL-001-Amide-PEG3-acid	Fluorescent Dye	Others
ABL-001-Amide-PEG3-acid, an analogue of ABL-001, is usually used as a labeled chemical or fluorescent probe.

HY-P1785

Abl Cytosolic Substrate Abltide	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus .

HY-142913

ABL-L	Apoptosis	Cancer
ABL-L induces apoptosis of human laryngocarcinoma cells through p53-dependent pathway.

HY-RS00102

ABL1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ABL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABL1 Human Pre-designed siRNA Set A ABL1 Human Pre-designed siRNA Set A

HY-RS00103

Abl1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Abl1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Abl1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abl1 Mouse Pre-designed siRNA Set A Abl1 Mouse Pre-designed siRNA Set A

HY-RS00104

ABL1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABL1 Rat Pre-designed siRNA Set A contains three designed siRNAs for ABL1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABL1 Rat Pre-designed siRNA Set A ABL1 Rat Pre-designed siRNA Set A

HY-RS00105

ABL2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABL2 Human Pre-designed siRNA Set A contains three designed siRNAs for ABL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABL2 Human Pre-designed siRNA Set A ABL2 Human Pre-designed siRNA Set A

HY-145887

*BCR-ABL1-IN-1*	Bcr-Abl	Neurological Disease
BCR-ABL1-IN-1 is a potent, orally active, and specific inhibitor of ABL kinase. BCR-ABL1-IN-1 has potential for elucidating the role of ABL kinases in the brain in non-clinical studies .

HY-169230

*BCR-ABL-IN-9*	Bcr-Abl	Cancer
BCR-ABL-IN-9 (Compound B1) is a *BCR-ABL* inhibitor that achieves sustained *BCR-ABL* suppression by forming stable covalent bonds with the *ABL* kinase. BCR-ABL-IN-9 is also effective in inhibiting the activity of the *ABL* kinase (IC₅₀ = 1.2 nM). BCR-ABL-IN-9 possesses anticancer activity .

HY-111872

*SNIPER(ABL)-020*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein .

HY-111858

*SNIPER(ABL)-050*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein .

HY-169231

*BCR-ABL-IN-10*	Bcr-Abl	Cancer
BCR-ABL-IN-10 (compound B4) is a covalent and aryl vinyl sulfate (AVS)-containing *BCR-ABL* inhibitor with an IC₅₀ of 43.1 nM for ABL kinase. BCR-ABL-IN-10 forms a covalent and stable adduct with ABL kinase, leading to sustained inhibition of endogenous BCR-ABL activities. BCR-ABL-IN-10 can be used for the study of chronic myeloid leukemia (CML) .

HY-111851

*SNIPER(ABL)-049*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 100 μM .

HY-126143

*CHMFL-ABL-039*	Bcr-Abl	Cancer
CHMFL-ABL-039 is a type II native *ABL* kinase and drug-resistant V299L mutant *BCR-ABL* inhibitor with the IC₅₀s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia .

HY-111860

*SNIPER(ABL)-013*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 20 μM .

HY-18819

*BCR-ABL-IN-2*	Bcr-Abl	Cancer
BCR-ABL-IN-2 is an inhibitor of *BCR-ABL1* tyrosine kinase, with IC₅₀s of 57 nM, 773 nm for ABL1 ^native and ABL1 ^T315I, respectively.

HY-111859

*SNIPER(ABL)-058*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 10 μM .

HY-111861

*SNIPER(ABL)-024*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 5μM .

HY-111854

*SNIPER(ABL)-015*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 5 μM .

HY-111873

*SNIPER(ABL)-019*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 0.3 μM .

HY-111874

*SNIPER(ABL)-039*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 10 nM. IC₅₀s are 0.54 nM, 10 nM, 12 nM, and 50 nM for *ABL*, cIAP1, cIAP2, XIAP, respectively .

HY-150566

*BCR-ABL-IN-5*	Bcr-Abl	Cancer
BCR-ABL-IN-5 (compound II) is a *Bcr-Abl* kinase** (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-Abl ^WT and Bcr-Abl ^T3151 with the IC₅₀ value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells .

HY-111862

*SNIPER(ABL)-044*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 10 μM .

HY-136526

*BCR-ABL-IN-3*	Bcr-Abl	Cancer
BCR-ABL-IN-3 is a potent and irreversible *Bcr-Abl* inhibitor with an IC₅₀ of ≤100 nM for Ba/F₃Bcr-Abl ^T3151. BCR-ABL-IN-3 has anti-cancer activity .

HY-153008

*BCR-ABL-IN-7*	Bcr-Abl	Cancer
BCR-ABL-IN-7 (compound 4) is a WT and T315I mutant ABL kinases inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research .

HY-111863

*SNIPER(ABL)-047*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 2 μM .

HY-150569

*BCR-ABL-IN-6*	Bcr-Abl	Cancer
BCR-ABL-IN-6 (9h) is a selective *Bcr-Abl* kinase inhibitor with IC₅₀s of 4.6 and 227 nM for *Bcr-Abl* ^WT and Bcr-Abl ^T3151** respectively. BCR-ABL-IN-6 inhibits *Bcr-Abl* kinase with strong affinity inside the cells with an EC₅₀ of 14.6 nM. BCR-ABL-IN-6 is an imatinib derivative which can be used for research of chronic myelogenous leukemia . BCR-ABL-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-119370

*CHMFL-ABL-121*	Bcr-Abl Apoptosis	Cancer
CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC₅₀s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively .

HY-111871

*SNIPER(ABL)-033*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 0.3 μM .

HY-101268

*CHMFL-ABL-053*	Bcr-Abl Src p38 MAPK	Cancer
CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available *BCR-ABL, SRC* and p38 kinase inhibitor with IC₅₀ values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively .

HY-139730

*c-ABL-IN-1*	Others	Neurological Disease
c-ABL-IN-1 is a novel selective *c-Abl* inhibitor that prevents neurodegeneration in parkinson’s disease.

HY-156148

*BCR-ABL-IN-8*	Bcr-Abl	Cancer
BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor containing trimethoxy group .

HY-142922

*BCR-ABL-IN-4*	Bcr-Abl	Cancer
BCR-ABL-IN-4 is a *BCR-ABL* inhibitor with anticancer effects. BCR-ABL-IN-4 inhibits the cancer cell growth with IC₅₀ values of 0.67 nM and 16 nM for K562 cells and BCR-ABL T315I transfected Ba/F3 cells, respectively (WO2021143927A1; compound 11) .

HY-101034

*CHMFL-ABL/KIT-155* CHMFL-Abl-KIT-155	Bcr-Abl c-Kit Apoptosis PDGFR Discoidin Domain Receptor	Cancer
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC₅₀s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC₅₀=81 nM), CSF1R (IC₅₀=227 nM), DDR1 (IC₅₀=116 nM), DDR2 (IC₅₀=325 nM), LCK (IC₅₀=12 nM) and PDGFRβ (IC₅₀=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis .

HY-146530

*c-ABL-IN-4*	Others	Neurological Disease Cancer
c-ABL-IN-4 is a potent inhibitor of *c-Abl. Activation of c-Abl* has been implicated in various diseases, notably cancer. c-ABL-IN-4 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 54) .

HY-146528

*c-ABL-IN-3*	Others	Neurological Disease Cancer
c-ABL-IN-3 is a potent inhibitor of *c-Abl. Activation of c-Abl* has been implicated in various diseases, notably cancer. c-ABL-IN-3 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 50) .

HY-156102

*c-ABL-IN-5*	Bcr-Abl	Neurological Disease
c-ABL-IN-5 is a selective c-Abl inhibitor with neuroprotective effects. c-ABL-IN-5 has blood-brain barrier penetrability, metabolic stability and good pharmacokinetic properties. When c-ABL-IN-5 is labeled with [18F] (compound [18F]3), it can be used as a tracer to evaluate disease-modifying efficacy by complementary positron emission tomography (PET). c-ABL-IN-5 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD) .

HY-163189

*c-ABL-IN-6*	Bcr-Abl	Neurological Disease
c-ABL-IN-6 (compound A6) is a *c-ABL* inhibitor with IC₅₀ value of 16.6 nM. c-ABL-IN-6 displays higher neuroprotective effects against SH-SY5Y cell death induced by MPP ⁺ (HY-W008719). c-ABL-IN-6 can be used for the research of neurodegenerative disorder .

HY-146527

*c-ABL-IN-2*	Bcr-Abl	Neurological Disease Cancer
c-ABL-IN-2 is a potent inhibitor of *c-Abl. Activation of c-Abl* has been implicated in various diseases, notably cancer. c-ABL-IN-2 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2020260871A1, compound 25) . c-ABL-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100314

*BCR-ABL-IN-1*	Bcr-Abl	Cancer
BCR-ABL-IN-1 is an inhibitor of *BCR-ABL* tyrosine kinase, with a pIC₅₀ of 6.46, and may be used in the research of chronic myelogenous leukemia.

HY-153415

*PROTAC BCR-ABL* Degrader-1**	PROTACs Bcr-Abl	Cancer
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1) is a PROTAC with a 2-oxoethyl linker. PROTAC BCR-ABL Degrader-1 induces *Bcr-Abl* degradation in a ubiquitinproteasom-dependent manner. PROTAC BCR-ABL Degrader-1 exhibits antiproliferative activity against K562 cells, and has the potential to study cancer .

HY-160174

*BCR-ABL* kinase-IN-3**	Bcr-Abl	Cancer
BCR-ABL kinase-IN-3 (example 1) is a potent inhibitor of *BCR-ABL* that plays an important role in acute myeloid leukemia (AML) research .

HY-160174A

*BCR-ABL* kinase-IN-3 (dihydrocholide)**	Bcr-Abl	Cancer
BCR-ABL kinase-IN-3 (dihydrocholide) (example 1) is a potent inhibitor of *BCR-ABL* that plays an important role in acute myeloid leukemia (AML) research .

HY-130297

*PROTAC BCR-ABL1 ligand 1*	Bcr-Abl	Cancer
PROTAC BCR-ABL1 ligand 1, compound GMB-475, is the ligand of PROTAC that allosterically targets *BCR-ABL1* protein and recruits the E3 ligase Von Hippel-Lindau, resulting in ubiquitination and subsequent degradation of BCR-ABL1 .

HY-18817

AFG210	Bcr-Abl FGFR Raf RET VEGFR	Cancer
AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC₅₀=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of *Abl* kinase .

HY-12083

PPY-A	Bcr-Abl	Cancer
PPY-A is a potent T315I mutant and wild-type *Abl* kinases inhibitor with IC₅₀s of 9 and 20 nM, respectively. PPY-A inhibits Ba⁄F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC₅₀s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML) .

HY-111852

GNF5-amido-Me PROTAC Abl binding moiety 2	Ligands for Target Protein for PROTAC	Cancer
GNF5-amido-Me, the GNF5 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library

2,930 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 2,930 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

HY-L129

Target Protein Ligand Library

43 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 43 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

HY-L080

Targeted Therapy Drug Library

107 compounds

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.

There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.

MCE carefully collects a unique of 107 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

HY-L016

Protein Tyrosine Kinase Compound Library

1,140 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,140 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L060

Cytoskeleton Compound Library

1,372 compounds

The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases.

MCE designs a unique collection of 1,372 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

HY-L079

Anti-Blood Cancer Compound Library

2,897 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2,897 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P5426

Abl protein tyrosine kinase substrate	Peptides	Others
Abl protein tyrosine kinase substrate is a biological active peptide. (Abltide is a peptide substrate for Abl Kinase (Abl protein tyrosine kinase), a partner in the gag-Abl fusion protein of the Abelson murine leukemia virus. Used in Western blot and kinase assay.)

HY-P1785

Abl Cytosolic Substrate Abltide	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-131669

Dasatinib metabolite M6 Dasatinib carboxylic acid	Classification of Application Fields Disease Research Fields Cancer	Drug Metabolite
Dasatinib metabolite M6 (Dasatinib carboxylic acid) is an oxidative metabolite of Dasatinib (HY-10181). Dasatinib is a potent and orally active dual Bcr-Abl and Src family tyrosine kinase inhibitor .

HY-108486

Herbimycin A	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Source classification Benzene Quinones Disease Research Fields	Bacterial Antibiotic
Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 ^v-src and p210 ^BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.

Species:	Human (4) Virus (5)
Tag:	His (5) Tag Free (1) GST (3)
Source:	HEK293 (4) Sf9 insect cells (4) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P71685

	ABL1 Protein, Human (GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	E. coli
	ABL1, Human (GST) is a non-receptor tyrosine-protein kinase. ABL1, Human is implicated in a wide range of cellular processes, including regulation of cell growth and survival, oxidative stress and DNA-damage responses, actin dynamics and cell migration, transmission of information about the cellular environment through integrin signaling.

HY-P77308

	ABL1 Protein, Human (sf9, GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	Sf9 insect cells
	ABL1 is a non-receptor tyrosine protein kinase that coordinates key cellular processes for growth and survival. It affects cytoskeletal remodeling, cell motility, and receptor endocytosis. ABL1 Protein, Human (sf9, GST) is the recombinant human-derived ABL1 protein, expressed by Sf9 insect cells , with N-GST labeled tag. The total length of ABL1 Protein, Human (sf9, GST) is 418 a.a., with molecular weight of ~65 kDa.

HY-P702716

	ABL1 Protein, Human (sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	Sf9 insect cells
	ABL1 is a non-receptor tyrosine protein kinase that coordinates key cellular processes for growth and survival. It affects cytoskeletal remodeling, cell motility, and receptor endocytosis. ABL1 Protein, Human (sf9) is the recombinant human-derived ABL1, expressed by Sf9 insect cells , with tag Free labeled tag. The total length of ABL1 Protein, Human (sf9) is 1104 a.a.,

HY-P73952

	*HA/Hemagglutinin Protein, Influenza B (ABL77299, HEK293, His)* HA; Hemagglutinin; HA/Hemagglutinin, Influenza B (B/Oita/15/1992, HEK293, His)	Virus	HEK293
	The hemagglutinin (HA) protein attaches viral particles to host cells by binding to sialic acid-containing receptors and induces viral particle internalization through clathrin-dependent endocytosis. HA also promotes an alternative clathrin- and caveolin-independent pathway for some virions. HA/Hemagglutinin Protein, Influenza B (ABL77299, HEK293, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag. The total length of HA/Hemagglutinin Protein, Influenza B (ABL77299, HEK293, His) is 551 a.a., with molecular weight of ~59.6 kDa.

HY-P73953

	*HA/Hemagglutinin Protein, Influenza B (ABL77244, sf9, His)* HA; Hemagglutinin; HA/Hemagglutinin, Influenza B (B/Victoria/02/1987, sf9, His)	Virus	Sf9 insect cells
	The hemagglutinin (HA) protein attaches viral particles to host cells by binding to sialic acid-containing receptors and induces viral particle internalization through clathrin-dependent endocytosis. HA also promotes an alternative clathrin- and caveolin-independent pathway for some virions. HA/Hemagglutinin Protein, Influenza B (ABL77244, sf9, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of HA/Hemagglutinin Protein, Influenza B (ABL77244, sf9, His) is 548 a.a., with molecular weight of ~58.87 kDa.

HY-P73954

	*HA1/Hemagglutinin Protein, Influenza B (ABL77244, HEK293, His)* HA; Hemagglutinin; HA/Hemagglutinin, Influenza B (B/Victoria/02/1987, HEK293, His)	Virus	HEK293
	The hemagglutinin (HA) protein attaches viral particles to host cells by binding to sialic acid-containing receptors and induces viral particle internalization through clathrin-dependent endocytosis. HA also promotes an alternative clathrin- and caveolin-independent pathway for some virions. HA/Hemagglutinin Protein, Influenza B (ABL77244, HEK293, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

HY-P703085

	ARG Protein, Human (Active, Sf9, GST) Tyrosine-protein kinase Abl2; Abelson murine leukemia viral oncogene homolog 2; Abelson tyrosine-protein kinase 2; Abelson-related gene protein; Tyrosine-protein kinase ARG; Abl2; AblL; ARG; Homo sapiens; Human Kinase; Transferase; Tyrosine-protein kinase; 2.7.10.2	Human	Sf9 insect cells

HY-P74912

	*HA1/Hemagglutinin Protein, Influenza B (ABL77255, HEK293, His)* Influenza B (B/Yamagata/16/1988) Hemagglutinin / HA1 Protein (HEK293, His)	Virus	HEK293
	The hemagglutinin HA1 protein is essential for attachment of virions to host cells by binding to sialic acid-containing receptors, inducing virion internalization via clathrin-dependent or clathrin- and caveolin-independent pathways.As a class I viral fusion protein, HA1 determines host range restriction and virulence, mediating fusion between the virion membrane and the endosomal membrane.HA1/Hemagglutinin Protein, Influenza B (ABL77255, HEK293, His) is the recombinant Virus-derived HA1/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

HY-P74913

	*HA1/Hemagglutinin Protein, Influenza B (ABL77101, HEK293, His)* Influenza B (B/Victoria/504/2000) Hemagglutinin / HA1 Protein (HEK293, His)	Virus	HEK293
	The hemagglutinin HA1 protein is essential for attachment of virions to host cells by binding to sialic acid-containing receptors, inducing virion internalization via clathrin-dependent or clathrin- and caveolin-independent pathways.As a class I viral fusion protein, HA1 determines host range restriction and virulence, mediating fusion between the virion membrane and the endosomal membrane.HA1/Hemagglutinin Protein, Influenza B (ABL77101, HEK293, His) is the recombinant Virus-derived HA1/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-12047S

Ponatinib-d8
Ponatinib-d₈ is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-15463S

Imatinib-d8 1 Publications Verification
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

HY-15463S1

Imatinib-d4
Imatinib-d₄ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

HY-10181S

Dasatinib-d8
Dasatinib-d₈ is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.

HY-10159S

Nilotinib-d6
Nilotinib-d₆ is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1].

HY-15463S2

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-107447S

N-Deshydroxyethyl Dasatinib-d8
N-Deshydroxyethyl Dasatinib-d₈ is the deuterium labeled N-Deshydroxyethyl Dasatinib. N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL[1].

HY-13904S

Flumatinib-d3
Flumatinib-d₃ is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively[1].

HY-132549S

Nilotinib-d3
Nilotinib-d₃ is the deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1][2].

HY-10159S1

Nilotinib-13C,d3
Nilotinib-13C,d3 is a deuterated labeled Nilotinib . Nilotinib is an orally available *Bcr-Abl* tyrosine kinase inhibitor with antineoplastic activity.

HY-10158S

Bosutinib-d8
Bosutinib-d₈ is a deuterium labeled Bosutinib. Bosutinib is a dual Src/Abl inhibitor with IC50s of 1.2 nM and 1 nM, respectively[1][2].

HY-133794S

Dasatinib N-oxide-d8
Dasatinib N-oxide-d₈ is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor[1][2].

HY-G0017S1

N-Desmethyl imatinib-d4
N-Desmethyl imatinib-d₄ is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N-Desmethyl imatinib-d₄ (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83458

	ABL2 Antibody (YA3203) Abl2; AblL; ARG; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; Abelson-related gene protein; Tyrosine-protein kinase ARG	WB, FC	Human, Mouse, Rat
	ABL2 Antibody (YA3203) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3203), targeting ABL2, with a predicted molecular weight of 128 kDa (observed band size: 128 kDa). ABL2 Antibody (YA3203) can be used for WB, FC experiment in human, mouse, rat background.

HY-P83171

	ETV6 Antibody (YA2916) ETV6; Tel; TEL oncogene; TEL/Abl; TEL1	WB, ICC/IF, FC	Human
	ETV6 Antibody (YA2916) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2916), targeting ETV6, with a predicted molecular weight of 53 kDa (observed band size: 53 kDa). ETV6 Antibody (YA2916) can be used for WB, ICC/IF, FC experiment in human background.

HY-P83095

	ABI2 Antibody (YA2840) Abelson interactor 2; ABI2; ABI2B; Abl binding protein 3; AblBP3; ArgBP1; ARGBPIA; ArgBPIB; SSH3BP2	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	ABI2 Antibody (YA2840) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2840), targeting ABI2, with a predicted molecular weight of 56 kDa (observed band size: 75 kDa). ABI2 Antibody (YA2840) can be used for WB, IHC-P, ICC/IF experiment in human, mouse, rat background.